• LAST PRICE
    1.4950
  • TODAY'S CHANGE (%)
    Trending Down-0.0050 (-0.3333%)
  • Bid / Lots
    1.4600/ 5
  • Ask / Lots
    1.5300/ 1
  • Open / Previous Close
    1.4600 / 1.5000
  • Day Range
    Low 1.4600
    High 1.4950
  • 52 Week Range
    Low 0.9548
    High 3.9900
  • Volume
    688
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.5
TimeVolumeBIAF
09:55 ET1001.46
12:12 ET3001.495
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBIAF
bioAffinity Technologies Inc
14.3M
-1.5x
---
United StatesPETV
PetVivo Holdings Inc
14.9M
-1.0x
---
United StatesPOAI
Predictive Oncology Inc
13.4M
-0.7x
---
United StatesNRXS
Neuraxis Inc
14.8M
-1.0x
---
United StatesICU
SeaStar Medical Holding Corp
18.3M
-0.2x
---
United StatesDROR
Dror Ortho-Design Inc
10.3M
-4.3x
---
As of 2023-12-07

Company Information

bioAffinity Technologies, Inc. is a biotechnology company. The Company is focused on addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as a targeted cancer treatment. The Company develops noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Its lead product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. Through its wholly owned subsidiary, OncoSelect Therapeutics, LLC, the Company’s research is engaged in the discoveries and advancement of cancer therapeutics that specifically and selectively target cancer cells. It is focused on expanding its platform technologies in developing tests that detect and therapies that target various types of cancer and potentially other diseases.

Contact Information

Headquarters
22211 West Interstate-10, Suite 1206SAN ANTONIO, TX, United States 78257
Phone
210-698-5334
Fax
916-443-1908

Executives

Executive Chairman of the Board
Steven Girgenti
President, Chief Executive Officer, Founder, Director
Maria Zannes
Chief Financial Officer, Principal Accounting Officer, Vice President
Michael Dougherty
Executive Vice President, Chief Science and Medical Officer
Vivienne Rebel
Executive Vice President, General Counsel, Secretary
Timothy Zannes

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.3M
Revenue (TTM)
$321.5K
Shares Outstanding
9.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.02
Book Value
$1.32
P/E Ratio
-1.5x
Price/Sales (TTM)
44.3
Price/Cash Flow (TTM)
---
Operating Margin
-2,256.55%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.